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Abstract
Background and purpose: Multi-arm non-inferiority (MANI) trials, here defined as non-inferiority trials with
multiple experimental treatment arms, can be useful in situations where several viable treatments exist for a disease
area or for testing different dose schedules. To maintain the statistical integrity of such trials, issues regarding both
design and analysis must be considered, from both the multi-arm and the non-inferiority perspectives. Little
guidance currently exists on exactly how these aspects should be addressed and it is the aim of this paper to
provide recommendations to aid the design of future MANI trials.
Methods: A comprehensive literature review covering four databases was conducted to identify publications
associated with MANI trials. Literature was split into methodological and trial publications in order to investigate the
required design and analysis considerations for MANI trials and whether they were being addressed in practice.
Results: A number of issues were identified that if not properly addressed, could lead to issues with the FWER,
power or bias. These ranged from the structuring of trial hypotheses at the design stage to the consideration of
potential heterogeneous treatment variances at the analysis stage. One key issue of interest was adjustment for
multiple testing at the analysis stage. There was little consensus concerning whether more powerful p value
adjustment methods were preferred to approximate adjusted CIs when presenting and interpreting the results of
MANI trials.
We found 65 examples of previous MANI trials, of which 31 adjusted for multiple testing out of the 39 that were
adjudged to require it. Trials generally preferred to utilise simple, well-known methods for study design and analysis
and while some awareness was shown concerning FWER inflation and choice of power, many trials seemed not to
consider the issues and did not provide sufficient definition of their chosen design and analysis approaches.
Conclusions: While MANI trials to date have shown some awareness of the issues raised within this paper, very few
have satisfied the criteria of the outlined recommendations. Going forward, trials should consider the
recommendations in this paper and ensure they clearly define and reason their choices of trial design and analysis
techniques.
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Background
Non-inferiority trials are used for determining if new
treatments are no more than a pre-determined amount
less efficacious than the current standard treatment.
They can be particularly advantageous in studies where
new treatments provide an alternative benefit to the pa-
tient or funder. This includes potentially being less inva-
sive, less toxic, less costly or less time-consuming to
administer. It is also becoming increasingly important
for trials to be able to run efficiently in order to provide
useful and potentially practice-changing information in a
timely manner. Currently, one way in which this extra
efficiency is achieved is by running trials with multiple
arms, where shared control data are compared with the
experimental arms. Multi-arm trials can reduce the cost
of running studies and decrease the required number of
patients to carry out a trial when compared to creating
separate trials for each experimental treatment option.
It is not uncommon for non-inferiority trials to in-
clude a third arm, further to the experimental and active
control arms. In a ‘gold-standard’ non-inferiority design
often defined thus within literature [1, 2], the third arm
would be a placebo, included to allow a test for assay
sensitivity, which ensures that the treatments being com-
pared for non-inferiority are not ineffective themselves.
Guidance from the European Medicines Agency (EMA)
states that, where ethically allowable, it is preferable for
a placebo arm to be included in non-inferiority trials [3].
It is less common for non-inferiority trials to include
multiple experimental arms than in a superiority setting,
despite the potential advantages of doing so.
There are a number of situations in which non-
inferiority trials with multiple experimental arms could
be, and indeed have been (see the “MANI trials in prac-
tice” section), useful. In disease areas where different vi-
able treatments exist, it would be preferable to test
multiple different (potentially new) treatments against
one another or against a common control simultan-
eously if any of the arms are preferable in terms of their
toxicity or cost. A trial may wish to test various doses of
the same treatment or different dosing discontinuation
schedules in order to ensure they still provide an accept-
able outcome to the standard treatment schedule. The
key difference between these scenarios is the relatedness
of the treatment arms and how the hypotheses for such
trials may be set up. Both scenarios are of interest within
this paper.
A common issue that can arise when carrying out ana-
lyses on any trial with multiple experimental arms is
potential inflation of the family-wise error rate (FWER),
that is, the probability of making at least one type I error
from a set of multiple comparisons. When carrying out
multi-arm non-inferiority trials, multiple comparisons
are made between treatment arms, either between one
another or against the control treatment(s). It is import-
ant in this case that we ensure the FWER is controlled
in order to reduce the chance of making erroneous
claims.
This paper investigates the methodology and current
conduct of frequentist fixed sample size trials with mul-
tiple experimental arms including either an active con-
trol arm (or arms) or a placebo arm, or both, where the
primary and/or key secondary hypotheses are analysed
in a non-inferiority framework. These will hereafter be
referred to as multi-arm non-inferiority (MANI) trials.
In order to do this, separate searches were carried out to
identify literature outlining methodological issues and
required considerations for MANI trials and to find ex-
amples of where such trials have been carried out in
practice.
The aims of this manuscript are to summarise the stat-
istical concerns raised in the literature around running
MANI trials and to assess whether or not these consid-
erations are addressed in practice, looking at current
and past trials. This will be done by first identifying the
key statistical issues involved in designing MANI trials
and the considerations required when addressing these
issues, before evaluating and comparing the methodo-
logical approaches that can be used when analysing
MANI trials. The first section will provide a high-level
outline of the statistical issues found with reference to
some of the available methods for addressing them.
These issues will affect both the design and analysis
phase of MANI trials but should all be considered within
the design phase as part of a statistical analysis plan for
a trial. In the second section, the conduct of current and
past MANI trials will be assessed and summarised in
order to show whether the issues raised are being ad-
dressed in practice. The research is brought together to
give recommendations for how MANI trials can be car-
ried out in practice and which methods are most appro-
priate to implement in different trial scenarios.
Literature search methodology
A comprehensive literature review was conducted to ob-
tain and analyse all current literature regarding statistical
methodology and design considerations required when
conducting MANI trials and all current and previous
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MANI trials that have been carried out. Search terms
were developed for the following major electronic data-
bases: MEDLINE (Ovid), EMBASE (Ovid), Science Cit-
ation Index (Web of Science) and the Cochrane Library
(Wiley), each from inception. The search terms are pro-
vided in Appendix A. The first search was conducted in
February 2020 and auto alerts were set up to ensure fur-
ther publications released prior to publication were not
missed. Additional publications were identified by
searching references and citations of useful literature.
From the original search, publications were split into
methodological literature and trial literature based on
title and abstract review, whereupon papers were read in
full to assess whether they were suitable for inclusion
within the review. The details of the search can be found
in Fig. 1.
In addition, an assessment of regulatory, guidance and
review documents on non-inferiority trials was carried
out to identify further possible trial considerations re-
quired that could be relevant. These mostly included
guidance documents and reviews from groups of
experts.
Methodological papers were considered in the MANI
setting and for ‘gold-standard’ non-inferiority trials (as
defined above); these were assessed to identify whether
they were also applicable in the MANI setting and
whether and how the methods changed when doing so.
If papers only considered methods for ‘gold standard’ tri-
als, they were excluded. Publications giving general guid-
ance around non-inferiority designs were also included,
as well as papers that gave more general guidance
around multiplicity adjustment. Other criteria for ex-
cluding methods based papers were Bayesian methods,
non-MANI methods (i.e. non-MANI and not ‘gold
standard’ design based methods), phase II trial methods
and papers where insufficient information was given to
add to the review (i.e. wider reviews of statistical consid-
erations in a disease area, comments on other methodo-
logical papers and abstracts for which further
information could not be found).
When searching for practical examples of MANI trials,
it was noticed that while the defined literature search
strategies identified the majority of such trials, not all
trial publications stated specifically that they were multi-
Fig. 1 Literature search flowchart
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arm designs and thus were not included in the results of
the original searches. Only MANI trials, i.e. those involv-
ing multiple experimental arms (as described in the
introduction), were included in the results presented in
this paper; three-arm ‘gold-standard’ non-inferiority tri-
als were excluded, as were trials on non-human subjects.
We considered trials without a placebo arm to be eli-
gible. The other exclusion criteria for trial papers were
non phase III trials, trials where MANI analyses were ex-
ploratory only, two-armed trials or trials where analyses
were not non-inferiority, abstracts and larger reviews of
several trials (in this case searches were carried out for
individual trials within these publications).
Statistical considerations for MANI trials
This section summarises the statistical issues and meth-
odology found within the literature review. When ini-
tially searching the methodological literature, there were
a large number of publications found that mentioned
multi-arm trials and that mentioned non-inferiority tri-
als, but few were found that considered both within the
same setting. Across the four databases searched, 68 pa-
pers were found that mentioned methodology within
non-inferiority trials with multiple arms, of which, upon
further reading, 9 were found to be directly applicable to
the scope of this review [4–12]. These papers cover a
variety of methodological areas concerning the design
and analysis of MANI trials. A further 17 papers were
found when searching references and citations of papers
found within the review. This larger number of papers,
being found from references rather than initial searches,
is primarily thought to be due to the FDA and EMA
guidance documents not appearing in the initial searches
in addition to papers that, while not exclusively written
as MANI specific methodology papers, still contain con-
cepts and ideas that can be applied within a MANI
framework, whether originally referring to multi-arm tri-
als (superiority or in general) or to two-arm or ‘gold-
standard’ (as previously defined) non-inferiority trials.
The next subsections outline and summarise the stat-
istical considerations that need to be made when design-
ing and analysing MANI trials. The need for these issues
to be addressed will change on a trial by trial basis. The
issues, in some cases, are not unique to MANI trials, but
may require an alternative approach or further thought
than is required in other types of trial. If not properly
addressed, the issues outlined may result in bias being
introduced into the trial or inflation/deflation of the type
I and type II errors of a trial which can ultimately under-
mine the ability to form strong conclusions from a trial
and trust any statistical inferences made.
Ordering and structuring of hypotheses
The setting up of hypotheses is a fundamental require-
ment for any clinical trial; they put the research question
into terms that trial data can seek to answer. Non-
inferiority trials have the added complexity of setting out
a suitable non-inferiority margin for the experimental
treatments and multi-arm trials have to consider
whether the implications of their hypotheses mean that
adjustment for multiple testing is required in order to
control the FWER of the trial. While adjustment for
multiple testing in clinical trials is not a new concept,
there are still issues around the best way to do so when
carrying out MANI trials, particularly in the analysis
stage (see later sections). If required, multiple testing ad-
justments can be made either through choice of trial de-
sign, through choice of analysis method or both.
The question of whether adjustment is required is an
area of strong debate within the literature. The recent
CONSORT extension for multi-arm trials stated that it
is “a challenging issue” and while advocating that trials
should state their reasons for adjusting or not adjusting,
they refrain from making explicit statements as to when
this should be done [13]. Determining whether adjust-
ment is warranted should be decided appropriately for
each trial after reviewing the literature. Some of the po-
tential areas to consider when designing a trial are sum-
marised throughout the remainder of this section along
with some of the schools of thought in these areas.
One of the key indicators as to whether multiplicity
adjustment may be required when analysing a multi-arm
trial with a shared control group is the structuring of the
hypotheses. Howard et al. (and references therein) [14]
summarise many of the current opinions within the lit-
erature around whether adjustment is required in multi-
arm trials, stating that most of the disagreement sur-
rounds the definition of a family of hypotheses. This
paper is not specific to MANI trials and generally uses
superiority trials within its examples, but the ideas can
be applied to all multi-arm trials with a shared control
group. The authors state that many views are “based on
philosophical opinion rather than statistical theory”.
Howard’s philosophy on the subject is that the order-
ing and nesting of the hypotheses is critical when mak-
ing a decision regarding adjustment [14]. Their criteria
for adjustment are that if hypotheses are used together
in order to make a single claim of efficacy and all indi-
vidual hypotheses have to be rejected in order to reject a
global hypothesis, then it is not necessary to adjust to
control the FWER; however, it may be necessary to ad-
just for the increased probability of observing multiple
type I errors simultaneously. If the hypotheses do not all
have to be rejected to claim efficacy (but they all form a
single claim of efficacy), then it is necessary to adjust to
control the FWER. If the arms lead to individual claims
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of efficacy, it is argued that no adjustment is required as
this is where the trial is being penalised for increased ef-
ficiency over carrying out multiple two-armed trials.
The decision of how to structure the hypotheses in
order to best answer a research question is also reflected
within the choice of power to be used within a trial.
Westfall and Young [15] give a summary of the different
possible choices of power and in which trial situations
they are appropriate, for both MANI and other types of
multi-arm trial. These include the all pair power, which
is the probability of correctly rejecting all false hypoth-
eses, the any pair power, which is the probability of cor-
rectly rejecting at least one false hypothesis and the per
pair power, which is the probability of rejecting a spe-
cific false hypothesis (generally the hypothesis of highest
interest).
This interest in specific trial arms can also be reflected
in the choice of contrast coefficients when comparing
multiple trial arms. Contrast tests are a useful strategy to
use when assessing multiple doses of an experimental
treatment, particularly within dose response detection
[16]. They involve applying different weights to trial
arms, whether to reflect an increasing dose in arms or to
allow comparison of trial arms against one another as
well as against a common control. Chang [4] looks at
using contrast tests in MANI and multi-arm superiority
trials with continuous, binary and survival endpoints and
summarises how different choices of contrast tests can
affect the power and the overall sample size.
Dmitrienko et al. [17] give a good summary of the dif-
ferent methods of setting up multiple hypothesis tests in
multi-arm trials (not specifically MANI) and which
methods require multiplicity adjustment. This includes
union-intersection (UI) and intersection-union (IU) test-
ing where either only one hypothesis must be rejected
for a global null hypothesis to be rejected or that all in-
dividual hypotheses must be rejected to do so. They also
summarise closed testing procedures and partitioning
tests which are more powerful than assessing hypotheses
on an individual basis while still allowing the FWER to
be strongly controlled. Closed testing procedures, one of
the more common methods of adjustment, involve cre-
ating a closed ‘family’ of hypotheses, for which every
intersection between hypotheses is tested at a local level;
hierarchical testing of hypotheses can correspond to
simple closed testing procedures. Partitioning tests in-
volve splitting unions of hypotheses into multiple, mutu-
ally exclusive hypotheses and testing them individually.
Hasler and Hothorn [5] use UI and IU testing princi-
ples in their procedures when assessing different ap-
proaches to analysing MANI trials with multiple
correlated endpoints. They summarise their preferred
analysis approaches for various hypothesis structures
and outline where adjustment for multiple testing is
required. These structures include global non-inferiority
where the alternative hypothesis for every treatment and
endpoint must be rejected in order to conclude non-
inferiority and testing for global non-inferiority for a
treatment group where alternative hypotheses for every
endpoint within a single arm must be rejected in order
to conclude non-inferiority for that arm.
Changing hypotheses when carrying out MANI trials
In addition to the initial considerations around the
structuring of the hypotheses, it may also be of interest
to change the hypothesis of a trial upon observation of a
result (preferably having pre-specified this possibility be-
fore running the trial). Typically, this is carried out when
switching from a non-inferiority test to a superiority test.
If this was to be carried out for a single experimental
arm and one endpoint and the primary endpoint re-
mains the same, then there is no increase in the possible
type I error as the switch corresponds to a simple closed
testing procedure [18]. However, the FDA [19] warn that
once multiple arms (or endpoints) are included in a trial
where non-inferiority and superiority are tested, there
can be inflation in the FWER and say that adjustment
may be required.
Ke et al. [20] look at the scenario where in addition to
switching from non-inferiority to superiority for a pri-
mary endpoint, another secondary endpoint is tested for
superiority in a hierarchical fashion. They discovered
that in this case, whether for a MANI trial or a two-
armed non-inferiority trial, the FWER can be inflated
and thus a suitable multiplicity adjustment should be
made. More specifically, without multiplicity adjustment,
“the type I error rate increases as the non-inferiority
margin gets larger and inflation is more severe for mod-
erately positive correlation between the two endpoints”.
This is addressed in Lawrence’s [10] paper where he de-
velops a closed testing procedure for the scenario de-
scribed in Ke et al.’s paper that suitably controls the
FWER even with multiple experimental treatments.
Zhong et al. [12] also address the issue of simultaneously
testing for non-inferiority and superiority in MANI tri-
als; their solution for ensuring strong control of the
FWER was to implement adjustment methods within
the trial analysis itself, rather than using a closed testing
procedure within the setup of the hypotheses.
Choice of non-inferiority margin definition and
subsequent analysis method when carrying out MANI
trials
The choice of method with which to assess non-
inferiority is dependent on whether it is possible to in-
clude a placebo arm within a trial. While acknowledging
the ethical issues around if it is appropriate to do so
(these are documented and summarised within ICH E10
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[21]), the EMA recommend that a placebo should be in-
cluded within a non-inferiority trial wherever possible
[3].
Huang et al. [7] outline that when a placebo arm can
be included within a MANI trial, there are two options
for how to set up the non-inferiority margin, with all
analysis methods falling into one of the two groups.
These are referred to as the “so-called fraction methods,
which formulate the NI margin as a fraction of the trial
sensitivity” (see Pigeot et al. for an example [22]) and the
approach where “the NI margin is expressed in terms of
the difference of the effects of the E (experimental) and
R (reference - referred to as control here)”. This is the
method applied in Kwong’s papers on hypothesis testing
procedures in MANI trials [8, 9] and according to
Huang is “more popular in clinical studies”.
In their guidance on selecting an appropriate non-
inferiority margin, the EMA [3] recommend that suffi-
cient thought is given as to the exact aims of the non-
inferiority trial before a decision is made on the choice
of analysis method. They argue against the use of frac-
tion based methods when the aim of the trial is “to show
that there is no important loss of efficacy if the test
product is used instead of the reference” and say they
are only suitable if the main aim of the trial is to show
that the experimental treatment is (or would be) super-
ior to placebo. They do not recommend a single best
method of analysis, but give guidance on possible con-
siderations depending on the state of the disease area.
If it is not possible to include a placebo arm within a
non-inferiority trial, the assay sensitivity of the control
arm can only be argued on a historical basis. In their
guidance on non-inferiority trials, the FDA [19] outline
two ways of approaching the analysis if this is the case:
the fixed margin approach and the synthesis method.
Both of these methods are within the second group
outlined by Huang et al. [7] where the NI margin is
given as an expression of the difference between the
experimental and control arms. The FDA guidance
does not mention the “fraction methods” spoken
about by Huang et al. which further illustrates their
point that the group of methods which set the NI
margin in terms of the difference between the control
and experimental treatment are more popular to use
in MANI trials.
The fixed margin approach is used as the basis for the
hypothesis testing methods for MANI trials seen in pa-
pers from Huang et al. [7], Kwong et al. [8, 9] and Zhong
et al. [12]. These methods are spoken about at greater
length in later sections of this paper and in Appendix B.
The synthesis and fraction based methods were only
briefly mentioned when talking about the set-up of hy-
pothesis testing in the MANI trial methodological
literature.
Increasing efficiency
A common issue with non-inferiority trials is that they
generally require a large sample size, especially in cases
where the non-inferiority margin is close to the esti-
mated effect of the control treatment. Kwong et al. [9]
explore optimisation of sample size within their paper,
with an algorithm that searches numerically for suitable
allocation ratios for the experimental and placebo arms
that reach the required any-pair power, enforcing that
neither can have a greater allocation than the control
arm. They then reduce the total sample size until it is no
longer possible to reach the required power.
For MANI trials designed to identify the minimal ef-
fective duration required from a number of experimental
arms, Quartagno et al. [11] advocate modelling the en-
tire duration-response curve and allocating patients to
different durations of treatment. They argue that doing
this avoids the potential issues caused when selecting
non-inferiority margins as well as reducing overall sam-
ple size. They also carried out simulations in order to as-
sess the ability of their duration response curves to
accurately reflect the true response curve when using
different numbers of duration arms, different increments
in duration and different flexible regression strategies in
the modelling process in order to make recommenda-
tions as to their optimal modelling strategy in different
trial scenarios.
Simultaneous confidence interval compatibility with p
value adjustment for controlling family-wise error rate
While it is possible to adjust for multiple testing within
the setup of the trial hypotheses, it may not always be
practical or within the frame of interest for the study to
do so. In some cases, adjustments will be made at the
analysis stage of the trial. There are many methods avail-
able for adjusting an analysis to account for potential in-
flation of the family-wise error rate; however, when
considering MANI trials, issues can arise when imple-
menting some of these methods, due to the results
which are used to make inferences in such trials.
Superiority trials often make statistical inferences from
p values while inferences from non-inferiority trials are
conventionally taken from confidence intervals (CIs). In
a standard two-arm randomised controlled trial where
no multiple testing is present, it is easily possible to ob-
tain both a p value and a CI for the treatment difference,
regardless of the framework of the trial, and the conclu-
sions with regard to efficacy of the treatment will agree.
However, when multiple testing is involved, there is less
information available on methods of adjusting a confi-
dence interval for multiplicity than there is for adjusting
p values [2].
In practice, for single-step adjustment scenarios, in the
case of p values, adjustments are made by first
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calculating a simple p value from a given hypothesis and
then comparing it to an adjusted critical value (or by
making an equivalent adjustment to the p value and
comparing it to a standard critical value). This can easily
be translated into creating adjusted CIs (whether for
treatment difference on a continuous scale, log odds ra-
tio or log hazards ratio etc.) using a standard confidence
interval formula with an altered critical value. This can
be done for Bonferroni testing and for Dunnett tests (an
adjusted version of this method is implemented in Has-
ler and Hothorn’s paper [5]).
In stepwise cases, that is, for methods such as the
Holm or Hochberg procedure where p values are or-
dered and tested sequentially against increasing or de-
creasing critical values, it is not easy to achieve
correspondence between an adjusted p value and an ad-
justed CI, with simple ad hoc methods of creating corre-
sponding adjusted CIs shown to lose overall coverage
[23]. Most adjusted CIs are all calculated together and
so are more commonly referred to as simultaneous CIs
(SCIs). There are contrasting messages in the literature
(summarised below) with some saying that for stepwise
adjustment methods, SCIs should be avoided while
others have made attempts at creating approximations
to stepwise p value adjustment methods for SCIs such as
the Holm, Hochberg and Hommel procedures. These
methods will be outlined in further detail in later
sections.
A good alternative to the outlined single step and step-
wise procedures is to use parametric methods of adjust-
ment such as Dunnett t testing and Tukey’s honestly
significant difference [24]. These methods provide the
added advantage of taking the correlation of the tests,
induced by the shared control group, into account while
non-parametric methods usually assume tests are carried
out independently of one another and can become more
conservative when this is not the case. They are designed
for continuous, normally distributed data and operate by
adjusting the method to calculate the standard error
such that the FWER can be strongly controlled. This al-
lows for the creation of critical values that can be used
to calculate SCIs which are less conservative than those
created using Bonferroni-based critical values. Tukey’s
method has the added advantage of being able to look at
pairwise comparisons between treatments while Dun-
nett’s method is designed only for comparisons between
treatment arms and a shared control treatment. Para-
metric step-up procedures also exist [25] which are even
more powerful than the previously mentioned methods
but suffer the same issue with lack of correspondence
when creating SCIs as the non-parametric stepwise
methods.
When looking at multiple testing procedures from a
superiority perspective, Phillips and an expert group [26]
state that the majority of discussants felt that using un-
adjusted confidence intervals is preferable when report-
ing results. It was felt that when choosing a multiple
testing procedure a “hypothesis test should take prefer-
ence” if a corresponding method is not available for cal-
culating an SCI. The reason given is that formal
hypothesis testing to establish an effect and creating a
CI is different to creating a CI based on a previously
established effect from a hypothesis test. For non-
inferiority and equivalence studies, the expert group
concluded, “compatible simultaneous CIs for the pri-
mary endpoint(s) should be presented in all cases”. This
is because in these studies, CIs are typically used to
make inferences regarding the hypotheses. The authors
regard compatibility (that is, the SCI having the same
conclusion as the adjusted p value) with the multiple
testing procedure as “crucial”.
Channon [27] is of the opinion that the conclusion
from CIs should always match those of p values. Al-
though outlining some methods of creating SCIs, he rec-
ommends that step-down multiple test procedures
“should not be used in circumstances where the confi-
dence interval is the primary outcome”. This is reasoned
using quotes from Hochberg and Tamhane [28] who
say, “if confidence estimates of pairwise differences are
desired then the only option is to use one of the single-
step procedures”. The examples given within the paper
are within a superiority setting; however, the comments
made about the use of step-down procedures are applic-
able to other trial settings.
A similar conclusion is made by Dmitrienko [29] with
regard to the use of SCIs. He concludes that in practice,
it is likely that the sponsor would have to use unadjusted
CIs for the treatment parameters rather than SCIs if
using a stepwise multiple testing procedure to adjust for
multiplicity.
It is possible to create approximate SCIs that closely
correspond to results from powerful stepwise p value ad-
justment procedures; however, when attempting to do
so, there are implications of a trade-off between com-
plexity and utility. Dmitrienko [29] provides an example
of a simple SCI that corresponds to the step-down Holm
procedure; however, these intervals are said to be “com-
pletely non-informative” with regard to providing infor-
mation on the parameter values. Efird and Nielsen [30]
provide a simple method for calculating SCIs based on
the Hochberg procedure for log odds ratios.
In order to improve the accuracy and utility of approx-
imated SCIs, more complex methodology is currently
under development. Guilbaud [31, 32] has developed
simultaneous confidence regions that correspond to
Holm, Hochberg and Hommel testing procedures. Al-
though these methods are in development and will likely
only continue to improve, the complexity of some of
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these methods may limit how often they will be applied
in practice. The decision as to whether or not to use
SCIs or an alternative method of analysis should be con-
sidered and justified accordingly on an individual trial
basis.
Accounting for heterogeneous treatment variances
Another way in which FWER can be inflated or deflated
when analysing MANI trials is if treatment variances are
heterogeneous. Many methods of analysis and sample
size calculations can assume that variances are homoge-
neous which, while appropriate in some trial scenarios,
may not be appropriate for others. Huang et al. [7] out-
line the effect of inappropriately assuming homogeneity
on the FWER and introduce two alternative procedures
that account for heterogeneity (these are outlined in
more detail in Appendix B). However, these methods
use hypothesis tests and it is not made clear whether
corresponding SCIs can be created from them and
whether they would reach the desired level of coverage.
Thus, this may feed further into the discussion around
whether it is preferable to base inferences on SCIs or on
p value/hypothesis test based analysis methods.
Maintaining sufficient power when strongly controlling
FWER
The draft FDA guidance on non-inferiority trials [33]
came under criticism from a group of European statisti-
cians who were concerned that there was an imbalance
between the recommendations on controlling the overall
type I error and ensuring that type II error was also pro-
tected [1]. It follows that by strongly controlling FWER,
and using conservative tests, there is a possibility that
false hypotheses may not be rejected. This is partly ad-
dressed by implementing more powerful testing proce-
dures, which enforces the importance of creating
suitable SCIs corresponding to powerful p value adjust-
ment methods. Hommel and Bretz [34] warn that there
is an element of trade-off between increased power and
reproducibility for different multiple test procedures so
this also needs to be taken into consideration on a case-
by-case basis. The other common but often less popular
method of increasing power is to increase the sample
size.
MANI trials in practice
In this section, we move on to summarise the current
conduct of past and present MANI trials and assess
whether the issues outlined in the previous sections are
presenting themselves frequently in practice and how
well they are being addressed when they arise. Where
areas are not being addressed or are not being addressed
sufficiently, we will try to identify possible reasons as to
why this may be and formulate recommendations on
how to improve how issues are dealt with.
Practical examples of MANI trials
Across the four databases searched, 65 examples of
MANI trials have been found to date. The original
search presented 137 papers, once repeats were re-
moved. Of these, 85 were removed, the majority of
which were papers relating to the same trials or abstracts
of trials that were already included (28). Twenty-six tri-
als did not have multiple experimental arms and four ei-
ther did not test both experimental arms for non-
inferiority or only included non-inferiority testing as an
exploratory measure. Sixteen publications were excluded
as they were Cochrane reviews of multiple trials in a dis-
ease area and therefore did not include design details of
individual trials. The remaining 11 exclusions were for
number of reasons including phase II or pilot studies,
trials on animals or publications being inaccessible.
Thirteen further trials were found, either from searching
for further details on abstracts, through references from
other trials and from methodological papers. The break-
down of this search is shown in Fig. 1.
Of the 65 found, 21 had been carried out across mul-
tiple countries, with the remainder taking place in a var-
iety of individual countries around the world and within
a variety of disease areas. The most common disease was
cancer (nine), with breast, lung, pancreatic and rectal in-
cluded among the MANI trials in this area. Six diabetes
trials were found and five trials were found in HIV and
pregnancy respectively, with all other disease areas hav-
ing four or less trials found. Table 1 gives a summary of
the MANI trials and some of their key characteristics
and conduct. When assessing whether multiple testing
was required, this was counted either based on where
trial publications had identified and reasoned the re-
quirement for it or where adjustment was judged to be
required based on Howard et al.’s recommendations
[14].
Of the 39 trials identified as requiring adjustment for
multiple testing, according to the criteria set out by
Howard et al. [14], 30 (77%) did so. This framework of
deciding whether adjustment was required, outlined in
the “Ordering and structuring of hypotheses” section,
was selected as it is straightforward to assess across trials
and was utilised in the creation of CONSORT guidance
on the topic. However, as also outlined in the “Ordering
and structuring of hypotheses” section, the topic of ad-
justment and its requirement in trials has many schools
of thought and so this is not the only possible option for
assessing the requirement. One trial adjusted for mul-
tiple testing despite not being identified as requiring it.
Of the adjustment methods implemented, 26 were
closed testing procedures or Bonferroni adjustment.
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Some trials included multiple methods of adjustment for
separate endpoints, for example, the LEAD-1 study [35]
used a closed testing procedure to adjust for the primary
endpoint while using Dunnett SCIs for the secondary
endpoint. Of the ‘other methods’ of adjustment, three
used Dunnett SCIs (not shown in the table as all used
closed testing procedures for the primary endpoint), two
used the Bonferroni-Holm method with p values, two
used Tukey’s method of multiple comparisons (one not
shown in the table as Bonferroni adjustment used for
the primary endpoint), one used a Hochberg based SCI
method and one used a Lan DeMets alpha spending
function as there were multiple stages within the trial.
Fifteen trials tested for superiority after proving non-
inferiority, 11 of these trials implemented a closed test-
ing procedure while four either chose to use Bonferroni
adjustment, or chose not to adjust at all. Other trials
which implemented closed testing procedures did so
when deciding whether to test further arms based on the
success of previous treatment arms. One such example
of this is the trial carried out by Bachelez et al. [36]
where two different doses of an experimental treatment,
tofacitinib, against a control treatment, etanercept and a
placebo. In this trial, a fixed sequence procedure was
outlined where the higher dose of the experimental
treatment was first to be tested for non-inferiority
against the control, then if successful, for superiority
against the placebo. If this was shown, both steps were
to be repeated for the lower dose of the experimental
treatment before finally testing the larger, then smaller
dose for superiority against the control treatment. As it
happened, the higher dose met the non-inferiority and
superiority criteria against the control and placebo re-
spectively but the lower dose did not meet the criteria
for non-inferiority against the control which meant that
no further hypotheses could be tested.
Heterogeneity of treatment variance was not consid-
ered in any of the MANI trials that were investigated.
Trials generally assumed homogenous variances or did
not mention the treatment variance within the publica-
tion. Only one trial mentioned the use of a dynamic
sample size calculation. This was due to a lack of avail-
ability of a sample size formula for their endpoint; Kroz
et al. therefore utilised a ‘marginal modelling approach
for correlated parameters based on general estimation
equations’ [37] which was developed by Rochon [38].
Table 1 Summary of conduct of MANI trials
No. of MANI trials assessed 65
Trial background and setup
No. trials with authors from primarily academic/industry backgrounds 56/9
No. trials with funding primarily from non-industry/industry sources 25/40
No. single centre/multi centre trials 10/55
No. with NI primary/key secondary endpoint 58/7
Design considerations
No. of trials that implemented a fixed margin approach (as outlined by FDA) 61
No. of trials that included a placebo arm 7
No. of trials that implemented a method to optimise sample size 1
Multiple testing
No. of trials where adjustment was required for multiple testing 39
No. of trials where adjustment was made for multiple testing 31
No. of trials adjusted with a closed testing procedure 14
No. of trials implementing Bonferroni adjustment 12
No. of trials implementing other methods of adjustment for multiple testing 5
No. of trials where superiority tested after NI proven 15
Analysis considerations
No. where heterogeneous treatment variance mentioned 0
No. of trials that clearly defined a choice of power 35
No. of trials that used all pair power/any pair power 11/24
Data type
No. trials with continuous MANI endpoint 34
No. trials with binary MANI endpoint 22
No. trials with survival MANI endpoint 9
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They state that due to their underestimation of dropout
levels, future trials in that disease area should have larger
sample sizes.
Of the trials assessed, only seven included a placebo
arm. The reasons for not including a placebo generally
were due to ethical issues or recruitment concerns. In
many cases, historical data had previously indicated the
efficacy of control treatments. The majority of trials
chose to implement what most closely resembled a fixed
margin approach as outlined within the FDA guidelines.
Some did not define an expected effect of the control
treatment and only defined a non-inferiority margin,
often with minimal explanation as to the decision behind
the choice of margin. Of the four trials that are said to
have not used it, there was no clear indication of what
design they implemented.
Statistical considerations of MANI trials in practice
Table 1 shows that while current and previous MANI
trials deal with some of the statistical issues identified in
this paper, there are issues that either rarely arise, or are
rarely addressed. In general, there was an indication that
trials showed a preference towards assumptions and
methods that would keep design and analysis simple. In
many cases, the failure to be explicit in providing rea-
soning around design choices may have been due to a
lack of awareness of the issues raised within the “Statis-
tical considerations for MANI trials” section.
The trials identified generally set up their hypotheses
in a manner similar to the fixed margin approach out-
lined by the FDA in their guidance [19]. The majority
did not have placebo arms and did not define an ex-
pected effect of the control arm. The trials that did use a
placebo stated that they used pre-specified non-
inferiority margins that were given in terms of the end-
point rather than as a percentage of the control treat-
ment. Despite failing to define all quantities used in the
FDA’s definition of a fixed-margin design, these values
may have been known and used implicitly when setting
a non-inferiority margin in many of the MANI trials and
therefore they have been counted as fixed-margin de-
signs. No trials used the fraction-based approaches men-
tioned by Huang [7]; this is likely due to the
requirement of a placebo arm in calculating an overall
test statistic, while the fixed margin approach uses a sep-
arate assay sensitivity hypothesis which may not require
testing if suitable evidence exists to suggest efficacy in
the active control arm.
Almost a quarter of the trials included the option to
test for superiority once non-inferiority had been con-
cluded The majority of these trials utilised a closed test-
ing procedure in order to adjust for multiple testing.
This seems to be a strong and simple approach to follow
when superiority is of interest and is clearly far more
efficient than carrying out separate trials to test non-
inferiority and superiority.
While power was mentioned in almost every trial, al-
most half did not explicitly state or strongly imply which
type was used. Three trials did consider two types of
power, looking at power for individual tests before giving
an ‘overall’ power. In some cases, it may have been as-
sumed that the choice would either be known or could
be inferred.
The closest that any trial came to sample size opti-
misation was the dynamic sample size calculation sum-
marised in the “Practical examples of MANI trials”
section, for which the resultant sample size was seen to
provide insufficient power to provide strong conclusions
for the trial. This method was implemented due to a lack
of availability of a sample size calculation for the chosen
testing strategy rather than to reduce the overall sample
size. There is potential for sample size optimisation to
be useful within MANI trials, particularly where funding
is an issue as non-inferiority trials can require greater
sample sizes than other trials. However, its utility must
be taken into consideration within the context of the
trial, taking into account whether it is key to reduce
sample size and how confident investigators are in their
estimates of treatment effect and variance.
It was noted that there were no trials that mentioned
having heterogeneous treatment variances or that men-
tioned carrying out any kind of assessment as to whether
an assumption of variance homogeneity was justified.
While it may be possible that all 65 trials were in areas
where treatment variances are all homogeneous, it could
be considered unlikely that is the case. Without know-
ledge of the treatments and the disease areas, it is diffi-
cult to know whether the assumption of homogeneous
variances (either explicitly or implicitly stated within the
trial publications) is fair. The publications outlining the
available analysis methods mentioned in the heterogen-
eity section have not been cited in any MANI trial publi-
cations to date which could mean that either they are
not well enough known by those carrying out such trials
or that there has simply not been a need for them to
date. Nonetheless, this is an area that may require more
careful consideration in trials going forward.
Adjustment for multiple testing was required for more
than half of the trials found. While the majority of trials
that required it implemented at least one method of ad-
justment, just over 20% of trials that were identified to
require adjustment failed to do so, with none of them
providing a reason for not adjusting. This is also the
situation with the choice of power, which may poten-
tially be due to a lack of awareness of the potential re-
quirement for adjustment or due to the investigators
believing that the reasoning could be inferred. It may be
that in cases where multiple doses of the same treatment
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are being tested, investigators see these as separate hy-
potheses rather than as part of the same family of hy-
potheses. If this is the case and each arm was tested in
its own right and did not provide an indication of overall
efficacy of a treatment, then adjustment would not be
required.
When considering adjustment for multiple testing in
the analysis phase, the choices of adjustment method
reflected the preference to utilise simple, well known
methods over more powerful but more complex
methods. While many trials used Bonferroni adjustment,
there were five other methods of adjustments imple-
mented across nine trials. Some trials chose to imple-
ment more powerful p value adjustment methods rather
than creating less powerful SCIs while others chose to
use Dunnett SCIs which are more powerful than Bonfer-
roni adjustment but more complex to understand. While
the figures showed a preference for utilising CIs rather
than switching to p values when analysing MANI trials,
the majority sacrificed power to detect non-inferiority to
do this.
Although it appears that trial teams prefer to imple-
ment simple adjustment methods within the analysis
phase, in a similar manner to adjustment within the de-
sign process, trials generally do not justify their choice
of adjustment method so it is difficult to know the
decision process when selecting one. When choosing
an adjustment method, it is vital to take the context
of the trial into account. If a small number of treat-
ments are being tested, raising the chances of a type
I error by a small amount, then the conservativeness
of simple adjustment methods such as Bonferroni
may be acceptable in order to take advantage of its
simplicity to implement. In cases where differences
between treatment effects are expected to be small, or
only just above the non-inferiority margin, more
powerful adjustment methods may be required to en-
sure that where truly non-inferior treatments exist,
they are found. In this case, it would be at the discre-
tion of the investigator as to whether they would pre-
fer the exact results offered by p values over the ease
of interpretation offered by approximate SCIs.
Recommendations
In this section, we provide specific recommendations for
the issues raised earlier within the paper that must be
considered when carrying out MANI trials. We further
give examples from previous MANI trial publications
where issues have appeared and been addressed appro-
priately. It is important to note that issues should be
considered within the context of each trial and thus
these recommendations may not provide a completely
exhaustive summary.
Clear definition of the structure of all hypotheses
It is vital to be clear within the design phase about how
the hypotheses of a MANI trial are to be structured. The
best choice of structuring is dependent on the aims of
the trial and which hypotheses are of the most interest.
Carrying out analysis for multiple hypotheses can in-
crease the chance of observing a type I error and this
may require addressing if hypotheses are used together
to form a single claim of efficacy for a treatment. The
decision as to whether or not adjustment is required
and, if applicable, whether this adjustment will be done
within the design of the trial or when carrying out the
analysis should be clearly outlined and reasoned within
any trial documentation (e.g. the protocol and statistical
analysis plan). It is particularly important to outline rea-
sons for not adjusting if it is not adjudged to be
necessary.
If adjustment is adjudged to be required, it can be ad-
dressed within the hypothesis setup by implementing a
closed testing procedure or similar sequential testing ap-
proach where certain hypotheses are only tested upon
the rejection of a previous hypothesis. In this case, the
order in which hypotheses are to be tested should be
considered and specified. This is generally useful when
testing different doses or testing schedules of the same
treatment in a trial, for example, the trial outlined by
Bachelez et al. [36] tested different doses of tofacitinib
within a closed testing procedure where the lower doses
of the experimental treatment were only tested if the
higher doses were seen to be non-inferior to the control.
Where it is of interest to know the results of all hy-
potheses, then sequential testing procedures are not ap-
propriate to use and adjustment may be required within
the analysis phase of the trial. If the treatment arms are
not related or the trial hypotheses do not form a single
claim of efficacy for a treatment then adjustment for
multiple testing may not be required as outlined in the
“Ordering and structuring of hypotheses” section.
Clear definition of the choice of power type
The choice of power type is strongly linked to the choice
of hypothesis structure. If all hypotheses are of identical
interest within a trial, then the power used should be the
all-pair power as outlined in the “Ordering and structur-
ing of hypotheses” section. If only one arm is of interest,
then either the any-pair power (probability of correctly
rejecting at least one false hypothesis) or the per-pair
power (probability of correctly rejecting a specified hy-
pothesis) could be utilised. It is important to be clear in
the choice of power or to define multiple powers if they
are of interest. The MAGENTA trial [39] provides a
good example of defining the two different powers they
implemented within their trial sample size calculation.
In this trial protocol paper, both the any-pair power and
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all-pair power is defined (expressed as power for each
test and overall power).
A priori specification of any change in hypothesis type
It is possible to include a change in hypothesis type in a
MANI trial; generally, this is testing for superiority once
non-inferiority has been proven. The easiest way to do
this is to set up a closed testing procedure or similar se-
quential testing procedure, as is seen in the BRIGHTER
trial [40] where for the key secondary endpoint, the ex-
perimental treatment was tested for superiority once
non-inferiority was concluded, as part of a closed testing
procedure. When including a hypothesis change in a
trial, it is important to specify this before the trial is car-
ried out in accordance with the Committee for Propri-
etary Medicinal Products guidance on switching
between superiority and non-inferiority [18]. This guid-
ance outlines the general considerations potentially re-
quired when switching hypotheses for MANI trials and
non-inferiority trials that fall outside the definition of a
MANI trial.
Clear definition of the choice of non-inferiority margin
and subsequent analysis method
In the “Choice of non-inferiority margin definition and
subsequent analysis method when carrying out MANI
trials” section, several methods for defining the non-
inferiority margin and subsequent analysis methods were
outlined. Trials generally chose to utilise the well-known
fixed-margin approach. The CONCENTRATE trial [41]
implemented this approach and provided a thorough ex-
planation as to how they had selected their non-
inferiority margin based on results seen in previous stud-
ies in the same disease area. Yuan et al. [42] also provide
a shorter but sufficiently clear definition of their non-
inferiority margin and its derivation. This is a perfectly
adequate method to use and has the added advantage of
not requiring the inclusion of a placebo arm which is
not true for all methods. The specially designed MANI
versions of the fixed margin approach outlined in the
“Choice of non-inferiority margin definition and subse-
quent analysis method when carrying out MANI trials”
section and detailed further in Appendix B may be
worth consideration as they can include adjustments for
multiple testing and can provide an increase in power
for tests. The normal fixed margin approach should be
considered the standard for MANI trials with explan-
ation only required if a different approach is chosen.
A priori specification of the choice of adjustment method
for multiple testing (where required) within a MANI trial
analysis with reasoning
If it is determined that adjustment for multiple testing is
required at the analysis stage of a MANI trial (see
recommendations on ordering and structuring of hy-
potheses for when this may be the case), then the choice
for whether to analyse using SCIs or adjusted p values
lies with the trial team. It may be preferable to imple-
ment two types of adjustment in a trial; for example,
LEAD-1 [35] implemented Dunnett testing for the pri-
mary endpoint of their trial and Bonferroni testing for
the safety endpoints, providing clear explanations for
each. The decision as to which adjustment methods are
implemented should be outlined in trial documents at
least briefly, with reasoning given for choice of method
if potentially unclear.
One of the strongest available options for carrying out
adjustment is to use parametric methods such as Dun-
nett t testing and Tukey’s honestly significant difference.
These methods provide correspondence for p values and
SCIs which is not true for the stepwise adjustment
methods outlined in the “Simultaneous confidence inter-
val compatibility with p value adjustment for controlling
family-wise error rate” section and are more powerful
than the single-step methods of adjustment such as Bon-
ferroni testing, which addresses some of the concerns
outlined in the “Maintaining sufficient power when
strongly controlling FWER” section. They also take ac-
count of potential correlation induced by having a
shared control group while many single-step and step-
wise procedures assume tests are carried out
independently.
The main reasons for which it may be preferable to
utilise a single-step method such as Bonferroni over the
parametric methods would be simplicity of implementa-
tion and a preference towards being conservative when
making inferences about treatments. If using a single-
step approach, it is preferable to create adjusted CIs as
these provide more detail on the uncertainty of estimates
and exact numerical values of treatment differences
compared to p values.
If the context of the trial dictates that stepwise adjust-
ment techniques should be implemented, based on
current research, it is preferable to use adjusted p values
or test statistics and critical values, as outlined in the
“Simultaneous confidence interval compatibility with p
value adjustment for controlling family-wise error rate”
section and Appendix B. Although methods for creating
approximate corresponding SCIs are available, their
complexity added to the availability of alternative
methods for creating SCIs means that they may not be
deemed worthwhile to implement.
Consideration of the potential requirement for
adjustment for heterogeneous treatment variances
The decision as to whether adjustment is required
within a trial analysis for heterogeneous treatment vari-
ances should be considered. Its requirement will entirely
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depend on the disease and treatment area and the confi-
dence for which an assumption of homogeneous treat-
ment variance can be made. If the treatment variances
are assumed homogenous, this should be stated with
reasoning within any trial publications where treatment
analysis will take place, with a full understanding of the
implications of falsely making such an assumption.
Where the assumption is not appropriate, alterations to
the analysis methods should be made that take variance
heterogeneity into account such as not using pooled
variance estimators otherwise there is a risk of inflation
or deflation of the FWER and potential loss of power.
Appropriate methods of accounting for heterogeneous
treatment variances are signposted in the “Accounting
for heterogeneous treatment variances” section and
within Appendix B.
Consideration of the potential use of sample size
optimising techniques
This is an optional consideration that can be imple-
mented within the design phase of a MANI trial, poten-
tially after the definition of non-inferiority margin and
subsequent analysis method. Non-inferiority trials can
require a large number of participants and thus it may
be of interest to try to reduce the overall sample size of
the trial, potentially with adjusted allocation ratios.
Kwong et al. [9] provide some examples of carrying out
sample size optimisation in MANI trials in their paper.
If carrying out sample size optimisation, it is important
to ensure that a sufficient level of power is maintained
within the trial.
Conclusions
In this paper, we have sought to identify some of the
statistical issues that can occur when designing and ana-
lysing Multi-Arm Non-Inferiority (MANI) trials, in order
to provide advice on considerations that should be made
and to recommend the most suitable methods to deal
with the issues where possible.
From our review of current MANI trials, it is clear that
with respect to the issues we identified, the obvious first
area for improvement comes in defining and explaining
the choices made for the design and analysis of trials in
a clear and concise manner. Explanations may be more
difficult to include in publications due to word counts,
but this can be included briefly, referenced or included
in an appendix. This point applies to all considerations
outlined within the “Statistical considerations for MANI
trials” section.
One issue that is of key importance throughout the
methodology is control of the FWER. It presents itself
both in the design and the analysis stage of a trial. The
design of the trial and structure of hypotheses determine
whether adjustment is required in the first place and the
actual adjustment process needs to consider choice of
method and assumptions made around the data. This is
an element that requires reflection on the debate sur-
rounding this topic when considering whether to adjust.
It is worth noting that while the review of MANI trials
in this paper found that of a number were adjudged to
require adjustment, many had not done so, this was
based on applying the philosophy of one of the schools
of thought in this area and the numbers could have been
different had a different philosophy been applied.
There were mixed messages across the literature in
some areas, particularly regarding adjustment for mul-
tiple testing at the design phase with compatibility issues
between SCIs and adjusted p values and the potential
advantages and disadvantages of using each within an
analysis. Further research may be required into the de-
velopment of SCIs that correspond to common stepwise
p value adjustment methods, particularly in creating
methods where complexity does not potentially inhibit
the ability to apply them widely in trial research. How-
ever, the parametric methods provide a strong alterna-
tive to stepwise methods and are relatively easy to apply.
The number of MANI trials found in the literature
search illustrated that while there is certainly a place for
such trials in modern research. Their benefits in terms
of increasing efficiency in finding treatments that may
be more cost effective, easier to administer or safer are
clear. Their use could increase in the future, particularly
as a greater number of treatments become available in
disease areas and endpoints such as quality of life are be-
coming of greater importance. The reason for their lim-
ited implementation to date may be for a number of
reasons. It may be that lack of familiarity with the design
or lack of available guidance for how to conduct MANI
trials discourages investigators from using them, or it
may be that general issues around multi-arm trials and
non-inferiority trials such as increased sample sizes may
discourage funding bodies from financing such trials.
The methodological literature search illustrated that
MANI trials are an area where there has not previously
been a large amount of research with little definitive
guidance available on how to run a MANI trial and on
any statistical considerations that need to be made fur-
ther to the standard considerations for multi-arm and
non-inferiority trials individually. The small number of
publications about methodology within MANI trials in-
dicates that there may be room for further exploration
of the topic. It was the aim of this review to keep the
search terms relatively wide in order to ensure that no
publications around MANI trials would be missed. How-
ever, a potential limitation is the number of publications
that were found from looking at references and citations
of publications rather than from the database searches
themselves. This could indicate that there may have
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been publications that could have been missed in the
search process which could have added to the scope of
this paper.
The trials analysed in this paper appeared to prefer
simple design and analysis choices and methods which
while not necessarily an issue on an individual basis will
not always be suitable for future trials. With potential to
be applied on a wider basis going forward, it is import-
ant that guidance is available so that those conducting
MANI trials are aware of any potential issues that they
need to be aware of and how to address them. This
paper aims to provide a good insight into the issues and
provide a good resource to refer to when setting up a
new MANI trial.
Appendix A
Literature review search strategies by database
MEDLINE
1. (non-inferior*) or (non?inferior*)
2. (three arm*) or (four arm*) or (five arm*) or (six
arm*) or (seven arm*) or (multi* arm*).mp.
3. 1 and 2
EMBASE
1. (non-inferior*) or (non?inferior*)
2. (three arm*) or (four arm*) or (five arm*) or (six
arm*) or (seven arm*) or (multi* arm*).mp.
3. 1 and 2
Web of Science
TOPIC: ((“non-inferior*” or “non?inferior*”)) AND
TOPIC: ((“three arm*” or “four arm*” or “five arm*” or
“six arm*” or “seven arm*” or “multi* arm*”))
Cochrane Library
1. MeSH descriptor: [Research Design] explode all
trees
2. MeSH descriptor: [Clinical Trials as Topic] explode
all trees
3. 1 or 2
4. (non inferior* or non??inferior*) and (three arm*) or
(four arm*) or (five arm*) or (six arm*) or (seven
arm*) or (multi* arm*)
5. 3 and 4
Appendix B
This appendix provides further detail around some of
the methodological ideas introduced in some of the
MANI specific literature mentioned in the first sections.
It was not included in the earlier sections in order to en-
sure that the extra information did not distract from the
primary aims of the paper.
Alternative methods of analysing MANI trials have
been outlined and developed by Kwong [8, 9] and Zhong
[12]. Their methods involve calculating test statistics and
comparing them to critical values that they calculate;
single-step, step-up and step-down procedures have
been developed that can test for both non-inferiority
and superiority (upon proving non-inferiority). These
methods more closely resemble p value adjustment
methods as they involve ordering of ‘most significant’
arms and increasing/decreasing critical values but they
do not directly correspond to the stepwise p value ad-
justment methods that have been mentioned, including
Holm and Hochberg. These methods work under the
fixed margin hypothesis framework outlined in the FDA
guidance [19] on carrying out non-inferiority analyses
and so generally assume the inclusion of a placebo arm
within a trial. They are all designed to strongly control
the FWER and are compared in their power to detect
non-inferiority and superiority which are generally of a
satisfactory level. There is no indication within their pa-
pers about how these methods compare to p value ad-
justment methods, however their ability to test for both
non-inferiority and superiority within the same frame-
work and their specific gearing towards MANI trials,
alongside their simplicity compared to some of the ap-
proximate SCI methods, are all positive indicators for
the methods. One of the disadvantages of these methods
are that making inferences based on test statistics is
similar to making them based on p values where they
are less easy to understand with regard to the magnitude
of the effect of a treatment compared to SCIs.
Kwong’s first paper [8] outlined an extension to the
fixed margin approach outlined in the FDA guidance
which allowed it to be utilised in MANI trials and cre-
ated appropriate test statistics for the single-step proced-
ure that they outlined. Huang et al. [7] utilised Kwong’s
single step procedure as the comparator for the two
methods they assessed for accounting for treatment vari-
ance heterogeneity when analysing MANI trials. The
methods assessed by Huang (both single step) were
shown to control FWER well for both homogeneous and
heterogeneous treatment variances and maintain a simi-
lar level of power to Kwong’s method. These methods
were published prior to Kwong’s and Zhong’s papers on
stepwise testing procedures and thus far have not been
formally compared with the methods from these papers,
nor has a stepwise method accounting for treatment
variance heterogeneity been formally outlined.
Hasler [6] considered similar areas to Huang’s paper
and derives separate test statistics, suitable for homoge-
neous or heterogeneous treatment variances, for trials
that include a placebo. These were created from a
fraction-based hypothesis framework and take multiple
testing into account where it is required. Hasler also
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extends to deriving lower SCIs for the ratios of differ-
ences before going on to discuss any pair power and al-
location optimisation. There are no comparisons made
between the Hasler’s methods and any other method
and they are not applied to formal examples to test their
ability to control FWER.
While the methods outlined by Hasler and Huang
have their individual merits, they both rely on the inclu-
sion of a placebo within a trial. There is also a lack of
comparisons between these methods and other available
methods in order to assess whether these methods truly
perform better in the presence of treatment variance
heterogeneity. In a trial setting, this variance heterogen-
eity may not be tested for, either due to prior knowledge
of the treatment arms or due to lack of awareness to the
issue and its potential consequences. However, Huang’s
results regarding the potential inflation of FWER if it is
not taken into account would suggest that it is some-
thing that should be considered and tested for.
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